Keyphrases
Graft-versus-host Disease (GvHD)
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
37%
Acute Myeloid Leukemia
33%
Myelodysplastic Syndrome
21%
Phase II Trial
14%
Decitabine
14%
Confidence Interval
11%
Hematopoietic Cell Transplantation
11%
Azacitidine
11%
Bronchiolitis Obliterans Syndrome
10%
Randomized Phase II Trial
10%
National Institutes of Health
10%
Granulocyte Colony-stimulating Factor (G-CSF)
10%
Overall Survival
10%
Clinical Trials
9%
COVID-19
8%
Non-relapse Mortality
8%
Failure-free Survival
8%
Transplantation
8%
Bone Marrow Plasma Cells
7%
Partial Response
7%
National Institutes of Health Consensus
7%
Leukemia
7%
Prednisone
7%
Initial Treatment
7%
Unrelated Hematopoietic Stem Cell Transplantation
7%
Ruxolitinib
7%
Chronic Myeloid Leukemia
7%
Late Acute
7%
Cardio-oncology
7%
B Cell Response
7%
Natural Killer Cells
7%
Ibrutinib
7%
Complete Response
7%
Group Reports
7%
Consensus Development
7%
Reduced-intensity Conditioning
6%
Unrelated Donor
6%
Stem Cell Mobilization
6%
Cyclophosphamide
6%
Conditioning Regimen
5%
Cell Therapy
5%
High Risk
5%
Cytomegalovirus Reactivation
5%
Health Response
5%
Plerixafor
5%
Memory B Cells
5%
Autologous Transplantation
5%
Systemic Therapy
5%
Engraftment
5%
Medicine and Dentistry
Chronic Graft Versus Host Disease
46%
Acute Myeloid Leukemia
26%
Hematopoietic Stem Cell
25%
Cell Transplantation
20%
Acute Graft Versus Host Disease
18%
Graft Versus Host Reaction
18%
Biological Marker
12%
Clinical Trial
11%
Myelodysplastic Syndrome
10%
Bronchiolitis Obliterans
10%
Azacitidine
10%
Decitabine
10%
Infection
9%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Disease
8%
Overall Survival
8%
Transplantation
8%
Allogeneic Stem Cell Transplantation
8%
Treatment Response
7%
Clinician
7%
Oncology
7%
Chronic Myelogenous Leukemia
7%
Receptor
7%
Ibrutinib
7%
Plerixafor
7%
Leukemia
6%
Symptom
6%
Myeloid Leukemia
5%
Cell Therapy
5%
Systemic Therapy
5%
Gene Frequency
5%
Failure Free Survival
5%
Immunology and Microbiology
Chronic Graft Versus Host Disease
50%
Graft-Versus-Host Disease
33%
Hematopoietic Cell
32%
Cell Transplantation
31%
Acute Graft Versus Host Disease
19%
Transplant Procedure
13%
Myeloid
12%
Bronchiolitis
11%
Conditioning
10%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Cytomegalovirus
7%
Blood Plasma
7%
Overall Survival
7%
Hematopoietic Stem Cell Transplantation
7%
Cyclophosphamide
7%
Prednisone
7%
Spike
7%
B Cell
7%
Natural Killer Cell
7%
Stem Cell Transplantation
7%
Engraftment
6%
Stem Cell
6%
Granulocyte Colony-Stimulating Factor
6%
Germinal Center
5%
Arm
5%